Physician profile
Manuel Lopez
NPI 1629176300
$31,995.49
in general payments reported to CMS, 2019-2025
33 companies · $3,628 in 2025
The $3,628 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,850 · 2020: $1,666 · 2021: $3,719 · 2022: $2,641 · 2023: $3,533 · 2024: $14K · 2025: $3,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,934 · Consulting Fee: $9,540 · Travel and Lodging: $1,456 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,933.72 |
| Consulting Fee | $9,540.00 |
| Travel and Lodging | $1,455.66 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $12,160.02 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $2,431.88 | 2019-2024 | Xarelto |
| Medtronic, INC. | $2,397.17 | 2021-2025 | Linq II, Cobalt Dr Mri Surescan, Corevalve Evolut R |
| Boston Scientific Corporation | $1,625.94 | 2019-2025 | Watchman Flx, Watchman Access System, Accolade Sr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,326.40 | 2019-2025 | Jardiance |
| Abbott Laboratories | $1,187.38 | 2019-2023 | Freestyle Libre 3 |
| Pfizer INC. | $1,145.11 | 2019-2025 | |
| Amgen INC. | $1,123.75 | 2019-2025 | Repatha, Tepezza, Repatha |
| Merck Sharp & Dohme LLC | $947.63 | 2021-2025 | Verquvo, Capvaxive |
| Atricure, INC. | $839.85 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $737.25 | 2019-2025 | |
| Novo Nordisk INC | $655.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic Vascular, INC. | $641.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $595.34 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $581.33 | 2019-2025 | Farxiga, Wainua |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $478.25 | 2021-2025 | |
| Esperion Therapeutics, INC. | $472.36 | 2021-2025 | Nexletol |
| Scpharmaceuticals INC. | $395.13 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $353.92 | 2024-2025 | Opsumit, Uptravi |
| Inari Medical, INC. | $351.38 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alnylam Pharmaceuticals INC. | $286.24 | 2022-2025 | Amvuttra |
| W. L. Gore & Associates, INC. | $249.36 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $239.56 | 2019 | |
| Shockwave Medical, INC | $181.37 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $173.22 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $128.42 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $123.15 | 2022-2024 | Assure Wcd |
| Regeneron Healthcare Solutions, INC. | $58.80 | 2019-2023 | Evkeeza |
| Abiomed | $31.10 | 2024 | Impella |
| Heartflow, INC. | $24.84 | 2023 | Ffrct |
| Kiniksa Pharmaceuticals, Ltd. | $23.17 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $16.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.